Growth factors are crucial regulators of cell differentiation towards tissue and organ development. Insulin and transforming growth factor-β (TGF-β) have been used as the major factors for chondrogenesis in vitro, by activating the AKT and Smad signaling pathways. Previous reports demonstrated that AKT and Smad3 have a direct interaction that results in the inhibition of TGF-β-mediated cellular responses. However, the result of this interaction between AKT and Smad3 during the chondrogenesis of human bone marrow-derived stem/progenitor cells (hBMSCs) is unknown. In this study, we performed functional analyses by inducing hBMSCs into chondrogenesis with insulin, TGF-β3 or in combination, and found that TGF-β3, when applied concomitantly with insulin, significantly decreases an insulin-induced increase in mRNA levels of the master regulator of chondrogenesis, SOX9, as well as the regulators of the 2 major chondrocyte markers, ACAN and COL2A1. Similarly, the insulin/TGF-β3-treated group presented a significant decrease in the deposition of cartilage matrix as detected by safranin O staining of histological sections of hBMSC micromass cultures when compared to the group stimulated with insulin alone. Intracellular analysis revealed that insulin-induced activation of AKT suppressed Smad3 activation in a dose-dependent manner. Accordingly, insulin/TGF-β3 significantly decreased the TGF-β3-induced increase in mRNA levels of the direct downstream factor of TGF-β/Smad3, CCN2/CGTF, compared to the group stimulated with TGF-β3 alone. On the other hand, insulin/TGF-β3 stimulation did not suppress insulin-induced expression of the downstream targets TSC2 and DDIT4/REDD1. In summary, insulin and TGF-β3 have antagonistic effects when applied concomitantly, with a minimal number of factors. The application of an insulin/TGF-β3 combination without further supplementation should be used with caution in the chondrogenic differentiation of hBMSCs.

Keywords:
Chondrogenesis, Insulin, AKT, Transforming growth factor-β, Smad3
1.
Akiyama, H. (2008) Control of chondrogenesis by the transcription factor Sox9. Mod Rheumatol 18: 213-219.
2.
Barry, F., R.E. Boynton, B. Liu, J.M. Murphy (2001) Chondrogenic differentiation of mesenchymal stem cells from bone marrow: differentiation-dependent gene expression of matrix components. Exp Cell Res 268: 189-200.
3.
Conery, A.R., Y. Cao, E.A. Thompson, C.M. Townsend Jr., T.C. Ko, K. Luo (2004) Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta-induced apoptosis. Nat Cell Biol 6: 366-372.
4.
Furumatsu, T., M. Tsuda, N. Taniguchi, Y. Tajima, H. Asahara (2005) Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 280: 8343-8350.
5.
Hara, E.S., M. Ono, P.T. Hai, W. Sonoyama, S. Kubota, M. Takigawa, T. Matsumoto, M.F. Young, B.R. Olsen, T. Kuboki (2015) Fluocinolone acetonide is a potent synergistic factor of TGF-beta3-associated chondrogenesis of bone marrow-derived mesenchymal stem cells for articular surface regeneration. J Bone Miner Res 30: 1585-1596.
6.
Hara, E.S., M. Ono, S. Kubota, W. Sonoyama, Y. Oida, T. Hattori, T. Nishida, T. Furumatsu, T. Ozaki, M. Takigawa, T. Kuboki (2013) Novel chondrogenic and chondroprotective effects of the natural compound harmine. Biochimie 95: 374-381.
7.
Ivkovic, S., B.S. Yoon, S.N. Popoff, F.F. Safadi, D.E. Libuda, R.C. Stephenson, A. Daluiski, K.M. Lyons (2003) Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 130: 2779-2791.
8.
Kawamura, M., M.R. Urist (1988) Growth factors, mitogens, cytokines, and bone morphogenetic protein in induced chondrogenesis in tissue culture. Dev Biol 130: 435-442.
9.
Kim, H.J., Y.J. Kim, G.I. Im (2009) Is continuous treatment with transforming growth factor-beta necessary to induce chondrogenic differentiation in mesenchymal stem cells? Cells Tissues Organs 190: 1-10.
10.
Kita, K., T. Kimura, N. Nakamura, H. Yoshikawa, T. Nakano (2008) PI3K/Akt signaling as a key regulatory pathway for chondrocyte terminal differentiation. Genes Cells 13: 839-850.
11.
Ko, J.Y., K.I. Kim, S. Park, G.I. Im (2014) In vitro chondrogenesis and in vivo repair of osteochondral defect with human induced pluripotent stem cells. Biomaterials 35: 3571-3581.
12.
Longobardi, L., L. O'Rear, S. Aakula, B. Johnstone, K. Shimer, A. Chytil, W.A. Horton, H.L. Moses, A. Spagnoli (2006) Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling. J Bone Miner Res 21: 626-636.
13.
Lorda-Diez, C.I., J.A. Montero, M.J. Diaz-Mendoza, J.A. Garcia-Porrero, J.M. Hurle (2011) Defining the earliest transcriptional steps of chondrogenic progenitor specification during the formation of the digits in the embryonic limb. PLoS One 6: e24546.
14.
Maeda, S. (2011) An impact of CCN2-BMP-2 complex upon chondrocyte biology: evoking a signalling pathway bypasses ERK and Smads? J Biochem 150: 219-221.
15.
Mueller, M.B., M. Fischer, J. Zellner, A. Berner, T. Dienstknecht, L. Prantl, R. Kujat, M. Nerlich, R.S. Tuan, P. Angele (2010) Hypertrophy in mesenchymal stem cell chondrogenesis: effect of TGF-beta isoforms and chondrogenic conditioning. Cells Tissues Organs 192: 158-166.
16.
Nishida, T., S. Kubota, T. Nakanishi, T. Kuboki, G. Yosimichi, S. Kondo, M. Takigawa (2002) CTGF/Hcs24, a hypertrophic chondrocyte-specific gene product, stimulates proliferation and differentiation, but not hypertrophy of cultured articular chondrocytes. J Cell Physiol 192: 55-63.
17.
Phornphutkul, C., K.Y. Wu, P.A. Gruppuso (2006) The role of insulin in chondrogenesis. Mol Cell Endocrinol 249: 107-115.
18.
Remy, I., A. Montmarquette, S.W. Michnick (2004) PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 6: 358-365.
19.
Ringe, J., G.R. Burmester, M. Sittinger (2012) Regenerative medicine in rheumatic disease-progress in tissue engineering. Nat Rev Rheumatol 8: 493-498.
20.
Runyan, C.E., H.W. Schnaper, A.C. Poncelet (2004) The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem 279: 2632-2639.
21.
Schmitz, N., S. Laverty, V.B. Kraus, T. Aigner (2010) Basic methods in histopathology of joint tissues. Osteoarthritis Cartilage 18(suppl 3): S113-S116.
22.
Song, K., S.C. Cornelius, M. Reiss, D. Danielpour (2003) Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem 278: 38342-38351.
23.
Steinert, A.F., G.D. Palmer, C. Pilapil, U. Noth, C.H. Evans, S.C. Ghivizzani (2009) Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. Tissue Eng Part A 15: 1127-1139.
24.
Suwanabol, P.A., S.M. Seedial, F. Zhang, X. Shi, Y. Si, B. Liu, K.C. Kent (2012) TGF-beta and Smad3 modulate PI3K/Akt signaling pathway in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 302: H2211-H2219.
25.
Takigawa, M. (2013) CCN2: a master regulator of the genesis of bone and cartilage. J Cell Commun Signal 7: 191-201.
26.
Yokoyama, K., M. Ikeya, K. Umeda, H. Oda, S. Nodomi, A. Nasu, Y. Matsumoto, K. Izawa, K. Horigome, T. Kusaka, T. Tanaka, M.K. Saito, T. Yasumi, R. Nishikomori, O. Ohara, N. Nakayama, T. Nakahata, T. Heike, J. Toguchida (2015) Enhanced chondrogenesis of induced pluripotent stem cells from patients with neonatal-onset multisystem inflammatory disease occurs via the caspase 1-independent cAMP/protein kinase A/CREB pathway. Arthritis Rheumatol 67: 302-314.
27.
Zhang, L., P. Su, C. Xu, J. Yang, W. Yu, D. Huang (2010) Chondrogenic differentiation of human mesenchymal stem cells: a comparison between micromass and pellet culture systems. Biotechnol Lett 32: 1339-1346.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.